annual CFF:
$133.16M-$101.12M(-43.16%)Summary
- As of today (July 11, 2025), ELVN annual cash flow from financing activities is $133.16 million, with the most recent change of -$101.12 million (-43.16%) on December 31, 2024.
- During the last 3 years, ELVN annual CFF has risen by +$134.18 million (+13206.79%).
- ELVN annual CFF is now -43.16% below its all-time high of $234.29 million, reached on December 31, 2023.
Performance
ELVN Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$234.00K-$39.74M(-99.41%)Summary
- As of today (July 11, 2025), ELVN quarterly cash flow from financing activities is $234.00 thousand, with the most recent change of -$39.74 million (-99.41%) on March 31, 2025.
- Over the past year, ELVN quarterly CFF has dropped by -$90.04 million (-99.74%).
- ELVN quarterly CFF is now -99.90% below its all-time high of $237.44 million, reached on March 31, 2023.
Performance
ELVN quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$43.13M-$90.04M(-67.61%)Summary
- As of today (July 11, 2025), ELVN TTM cash flow from financing activities is $43.13 million, with the most recent change of -$90.04 million (-67.61%) on March 31, 2025.
- Over the past year, ELVN TTM CFF has dropped by -$43.99 million (-50.49%).
- ELVN TTM CFF is now -81.67% below its all-time high of $235.23 million, reached on March 31, 2023.
Performance
ELVN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ELVN Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -43.2% | -99.7% | -50.5% |
| 3 y3 years | +10000.0% | -42.8% | +10000.0% |
| 5 y5 years | +2.0% | - | - |
ELVN Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -43.2% | +7502.2% | -99.9% | +108.3% | -81.7% | +2497.4% |
| 5 y | 5-year | -43.2% | +7502.2% | -99.9% | +108.3% | -81.7% | +2497.4% |
| alltime | all time | -43.2% | +7502.2% | -99.9% | +108.3% | -81.7% | +2497.4% |
ELVN Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $234.00K(-99.4%) | $43.13M(-67.6%) |
| Dec 2024 | $133.16M(-43.2%) | $39.97M(+3478.5%) | $133.16M(+42.8%) |
| Sep 2024 | - | $1.12M(-38.2%) | $93.28M(+1.7%) |
| Jun 2024 | - | $1.81M(-98.0%) | $91.74M(+5.3%) |
| Mar 2024 | - | $90.27M(>+9900.0%) | $87.11M(-62.8%) |
| Dec 2023 | $234.29M | $90.00K(-121.2%) | $234.29M(+1.1%) |
| Sep 2023 | - | -$425.00K(-84.9%) | $231.82M(-0.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2023 | - | -$2.82M(-101.2%) | $232.41M(-1.2%) |
| Mar 2023 | - | $237.44M(<-9900.0%) | $235.23M(<-9900.0%) |
| Dec 2022 | -$1.80M(+77.1%) | -$2.38M(-1549.4%) | -$1.80M(-411.2%) |
| Sep 2022 | - | $164.00K(+3180.0%) | $578.00K(+39.6%) |
| Jun 2022 | - | $5000.00(-98.8%) | $414.00K(+1.2%) |
| Mar 2022 | - | $409.00K | $409.00K |
| Dec 2021 | -$1.02M(-100.8%) | - | - |
| Dec 2020 | $130.51M | - | - |
FAQ
- What is Enliven Therapeutics, Inc. annual cash flow from financing activities?
- What is the all time high annual CFF for Enliven Therapeutics, Inc.?
- What is Enliven Therapeutics, Inc. annual CFF year-on-year change?
- What is Enliven Therapeutics, Inc. quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Enliven Therapeutics, Inc.?
- What is Enliven Therapeutics, Inc. quarterly CFF year-on-year change?
- What is Enliven Therapeutics, Inc. TTM cash flow from financing activities?
- What is the all time high TTM CFF for Enliven Therapeutics, Inc.?
- What is Enliven Therapeutics, Inc. TTM CFF year-on-year change?
What is Enliven Therapeutics, Inc. annual cash flow from financing activities?
The current annual CFF of ELVN is $133.16M
What is the all time high annual CFF for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. all-time high annual cash flow from financing activities is $234.29M
What is Enliven Therapeutics, Inc. annual CFF year-on-year change?
Over the past year, ELVN annual cash flow from financing activities has changed by -$101.12M (-43.16%)
What is Enliven Therapeutics, Inc. quarterly cash flow from financing activities?
The current quarterly CFF of ELVN is $234.00K
What is the all time high quarterly CFF for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. all-time high quarterly cash flow from financing activities is $237.44M
What is Enliven Therapeutics, Inc. quarterly CFF year-on-year change?
Over the past year, ELVN quarterly cash flow from financing activities has changed by -$90.04M (-99.74%)
What is Enliven Therapeutics, Inc. TTM cash flow from financing activities?
The current TTM CFF of ELVN is $43.13M
What is the all time high TTM CFF for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. all-time high TTM cash flow from financing activities is $235.23M
What is Enliven Therapeutics, Inc. TTM CFF year-on-year change?
Over the past year, ELVN TTM cash flow from financing activities has changed by -$43.99M (-50.49%)